Circulating tumor DNA is a prognostic biomarker in metastatic melanoma patients treated with chemoimmunotherapy and BRAF inhibitor.

Kalle E MattilaSiru MäkeläSoili KytöläEmma AnderssonPia VihinenSusan RamadanTanja SkyttäLeena TiainenMeri-Sisko VuoristoKristiina Tyynelä-KorhonenJussi KoivunenLaura KohtamäkiKristiina AittomäkiMicaela Hernberg

Published in: Acta oncologica (Stockholm, Sweden) (2022)

Higher pretreatment plasma ctDNA levels and sustained detectable plasma ctDNA levels during treatment indicated poor prognosis in metastatic melanoma patients.

Keyphrases

circulating tumor
poor prognosis
cell free
circulating tumor cells
end stage renal disease
long non coding rna
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
patient reported outcomes